» Articles » PMID: 27486046

Inflammasomes Link Vascular Disease with Neuroinflammation and Brain Disorders

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The role of inflammation in neurological disorders is increasingly recognised. Inflammatory processes are associated with the aetiology and clinical progression of migraine, psychiatric conditions, epilepsy, cerebrovascular diseases, dementia and neurodegeneration, such as seen in Alzheimer's or Parkinson's disease. Both central and systemic inflammatory actions have been linked with the development of brain diseases, suggesting that complex neuro-immune interactions could contribute to pathological changes in the brain across multiple temporal and spatial scales. However, the mechanisms through which inflammation impacts on neurological disease are improperly defined. To develop effective therapeutic approaches, it is imperative to understand how detrimental inflammatory processes could be blocked selectively, or controlled for prolonged periods, without compromising essential immune defence mechanisms. Increasing evidence indicates that common risk factors for brain disorders, such as atherosclerosis, diabetes, hypertension, obesity or infection involve the activation of NLRP3, NLRP1, NLRC4 or AIM2 inflammasomes, which are also associated with various neurological diseases. This review focuses on the mechanisms whereby inflammasomes, which integrate diverse inflammatory signals in response to pathogen-driven stimuli, tissue injury or metabolic alterations in multiple cell types and different organs of the body, could functionally link vascular- and neurological diseases and hence represent a promising therapeutic target.

Citing Articles

Nicotinamide N-oxide Inhibits Microglial Pyroptosis by Upregulating Mitophagy and Alleviates Neural Damage in Rats after TBI.

Li X, Luo L, Duan P, Bi Y, Meng Y, Zhang X Inflammation. 2024; .

PMID: 39472380 DOI: 10.1007/s10753-024-02171-7.


A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies.

Frazier H, Braun D, Bailey C, Coleman M, Davis V, Dundon S Brain Behav Immun Health. 2024; 40:100826.

PMID: 39161874 PMC: 11331815. DOI: 10.1016/j.bbih.2024.100826.


[Correlations between serum BDNF, IL-18 and hs-CRP levels in patients with acute cerebral infarction and vascular cognitive impairment].

Li J, Xu L, Li M, Song Y, Zhang J, Jia L Beijing Da Xue Xue Bao Yi Xue Ban. 2024; 56(4):708-714.

PMID: 39041569 PMC: 11284472.


Mind the Metabolic Gap: Bridging Migraine and Alzheimer's disease through Brain Insulin Resistance.

Del Moro L, Pirovano E, Rota E Aging Dis. 2024; 15(6):2526-2553.

PMID: 38913047 PMC: 11567252. DOI: 10.14336/AD.2024.0351.


Tachol1 QTL on mouse chromosome 1 is responsible for hypercholesterolemia and diet-induced obesity.

Kim J, Simpkins M, Williams N, Cimino E, Simon J, Richmond T Mamm Genome. 2024; 35(3):324-333.

PMID: 38837040 PMC: 11339885. DOI: 10.1007/s00335-024-10045-4.


References
1.
Najjar S, Pearlman D, Alper K, Najjar A, Devinsky O . Neuroinflammation and psychiatric illness. J Neuroinflammation. 2013; 10:43. PMC: 3626880. DOI: 10.1186/1742-2094-10-43. View

2.
Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P . Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 1995; 202(1-2):17-20. DOI: 10.1016/0304-3940(95)12192-7. View

3.
Honda H, Nagai Y, Matsunaga T, Okamoto N, Watanabe Y, Tsuneyama K . Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol. 2014; 96(6):1087-100. DOI: 10.1189/jlb.3A0114-005RR. View

4.
Lopez-Castejon G, Brough D . Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011; 22(4):189-95. PMC: 3714593. DOI: 10.1016/j.cytogfr.2011.10.001. View

5.
Heneka M, Carson M, El Khoury J, Landreth G, Brosseron F, Feinstein D . Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388-405. PMC: 5909703. DOI: 10.1016/S1474-4422(15)70016-5. View